Association between poor therapy adherence to inhaled corticosteroids and tiotropium and morbidity and mortality in patients with COPD
Authors Koehorst-ter Huurne K, Groothuis-Oudshoorn CGM, vanderValk PDLPM, Movig KLL, van der Palen J, Brusse-Keizer M
Received 3 January 2018
Accepted for publication 19 March 2018
Published 24 May 2018 Volume 2018:13 Pages 1683—1690
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Kirsten Koehorst-ter Huurne,1 Catharina GM Groothuis-Oudshoorn,2 Paul DLPM vanderValk,1 Kris LL Movig,3 Job van der Palen,4,5 Marjolein Brusse-Keizer4
1Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, the Netherlands; 2Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands; 3Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, the Netherlands; 4Medical School Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 5Department of Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede, the Netherlands
Aim: The aim of this study was to analyze the association between therapy adherence to inhaled corticosteroids (ICSs) and tiotropium on the one hand and morbidity and mortality in COPD on the other hand.
Methods: Therapy adherence to ICSs and tiotropium over a 3-year period of, respectively, 635 and 505 patients was collected from pharmacy records. It was expressed as percentage and deemed optimal at ≥75–≤125%, suboptimal at ≥50%–<75%, and poor at <50% (underuse) or >125% (overuse). The association between adherence and time to first hospital admission for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community acquired pneumonia (CAP), and mortality was analyzed, with optimal use as the reference category.
Results: Suboptimal use and underuse of ICSs and tiotropium were associated with a substantial increase in mortality risk: hazard ratio (HR) of ICSs was 2.9 (95% CI 1.7–5.1) and 5.3 (95% CI 3.3–8.5) and HR of tiotropium was 3.9 (95% CI 2.1–7.5) and 6.4 (95% CI 3.8–10.8) for suboptimal use and underuse, respectively. Suboptimal use and overuse of tiotropium were also associated with an increased risk of CAP, HR 2.2 (95% CI 1.2–4.0) and HR 2.3 (95% CI 1.2–4.7), respectively. Nonadherence to tiotropium was also associated with an increased risk of severe AECOPD: suboptimal use HR 3.0 (95% CI 2.01–4.5), underuse HR 1.9 (95% CI 1.2–3.1), and overuse HR 1.84 (95% CI 1.1–3.1). Nonadherence to ICSs was not related to time to first AECOPD or first CAP.
Conclusion: Poor adherence to ICSs and tiotropium was associated with a higher mortality risk. Furthermore, nonadherence to tiotropium was associated with a higher morbidity. The question remains whether improving adherence can reduce morbidity and mortality.
Keywords: COPD, adherence, morbidity, mortality, pneumonia, exacerbation, hospitalization
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]